Prognostic Value of m6A RNA Methylation Modulators and Potential Clinical Application in Pancreatic Cancer

Lianzi Wang  
First Affiliated Hospital of Anhui Medical University  
https://orcid.org/0000-0002-4694-6817

Huimin Li  
First Affiliated Hospital of Anhui Medical University

Tao Li  
First Affiliated Hospital of Anhui Medical University

Huihui Wang  
First Affiliated Hospital of Anhui Medical University

Xuemei Li  
First Affiliated Hospital of Anhui Medical University

Enjun Xu  
First Affiliated Hospital of Anhui Medical University

Qiuli Chen  
First Affiliated Hospital of Anhui Medical University

Yuanhong Xu  
First Affiliated Hospital of Anhui Medical University

shubing Zhang  
First Affiliated Hospital of Anhui Medical University

Research article

Keywords: pancreatic cancer, m6A RNA methylation modulators, YTHDF1, ALKBH5, METTL3, METTL14, KIAA1429, risk score, prognostic

DOI: https://doi.org/10.21203/rs.3.rs-43695/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

m6A is the most prevalent and abundant form of mRNA modification and plays a dual role in cancer development. The high incidence and mortality of pancreatic cancer are critical obstacles worldwide. In this study, we investigated the function of m6A RNA methylation modulators in pancreatic cancer.

Methods

Expression of 13 m6A RNA methylation modulators and clinical data from patients with pancreatic adenocarcinoma were obtained from TCGA database. Differences in the expression of 13 m6A RNA methylation modulators between tumour (n = 178) and healthy (n = 4) samples were compared by Wilcoxon test. LASSO Cox regression was used to select m6A RNA methylation modulators for analysis of the relationship between expression and clinical characteristics by univariate and multivariate regression. The pathways of the m6A RNA methylation modulators were examined by gene set enrichment analysis (GSEA) and we found enrichment in chemokine, ribosome, and mTOR signalling pathways.

Results

WTAP had a low expression in tumour samples compared with healthy samples. Furthermore, our analyses revealed that the m6A RNA methylation modulators YTHDF1, ALKBH5, METTL3, METTL14, and KIAA1429 correlated with high-risk patients, resulting in an elevated risk score and a lower overall survival. High-risk score correlated with clinical characteristic and was an independent prognostic indicator for pancreatic adenocarcinoma. The pathways involved were identified by GSEA to explore the potential mechanism of action.

Conclusion

Modulators involved in m6A RNA methylation were associated with the development of pancreatic cancer. A risk score based on the expression of YTHDF1, ALKBH5, METTL3, METTL14, and KIAA1429 may be an independent prognostic indicator.

1. Background

Pancreatic cancer is an aggressive cancer of the digestive system with high morbidity and mortality. Data from the National Centre for Health Statistics (NCSH) show a reduction in the occurrence of breast cancer, colorectal cancer, and prostate cancer in the past decade, but the incidence of pancreatic cancer continues to increase and it has become the fourth leading cause of cancer death [1]. Studies have predicted that it could be the second leading cause of cancer death by 2030 [2]. The estimated incidence of pancreatic cancer in the United States in 2020 is around 57,600 with a projected 47,050 deaths, which indicates a mortality above 80% [1]. Furthermore, the 5-year survival rate of pancreatic cancer is 9% and is the lowest across all types of cancer. Pancreatic adenocarcinoma (PAAD) is the most common type of pancreatic cancer, which encompasses up to 85% of pancreatic cancer [2]. While the precise cause and underlying mechanisms of PAAD are still unclear, genetics is an important factor related to tumour development and mutations in DNA or RNA may also drive the initiation of PAAD [3].

RNA modification is a crucial part of epigenetics, which together with gene and protein modification play an important role in the regulation of cellular processes. Interest in this field has been rising in recent year and according to the data
from the MODOMICS update in 2017, 163 different modifications have been identified in RNA molecules so far including N1-methyladenosine, N7-methyladenosine, 5-methylcytosine, pseudouridine, N6,2'-O-dimethyladenosine (m6A) and 2'-O-methylation. In eukaryotes, m6A is the most prevalent and abundant form of mRNA modification, which was identified in the 1970s. m6A is a dynamic and reversible process of mRNA modification and has been widely studied, although the exact mechanism of m6A modification remains unelucidated due to the technical limitations. The formation of m6A is composed of three individual proteins and it is possible to detect these m6A proteins as a reflection of m6A modification. The m6A modulator proteins are classified into three categories: writers, erasers, and readers. Writer proteins mainly include METTL3, METTL14, and WTAP. RBM15, ZC3H13, and KIAA1429 have been newly identified and play a role in mediating the formation of the writer protein complex. These writer proteins transfer the methyl group from S-adenosyl methionine to the RNA nucleotides. Erasers on the other hand are demethylases and remove the methyl group from the RNA molecule. Members of this group include FTO and ALKBH5. Finally, reader proteins recognise m6A modification and include YTHDF1, YTHDF2, YTHDF3, YTHDC1, YTHDC2, and the newly discovered HNRNPC.

m6A plays a vital role in the splicing, translation, and stability of RNA and regulates chromatin state and transcription. This has significant consequences in various human diseases where m6A alterations may enhance heart failure and influence brain development and function, immune response to viral infection, and bone metabolism. An increasing amount of evidence indicates that m6A RNA methylation modulators are associated with the development and progression of several malignant tumours. In bladder cancer, m6A modulator METTL3 promotes the expression of oncogenes including MYC and AF4. Furthermore, YTHDF1 has been linked with EIF3C that leads to the occurrence and metastasis of ovarian cancer. Studies have also found that m6A RNA methylation modulators cause genetic alterations across diverse cancer types including mutations and copy number variations. Moreover, m6A RNA methylation modulators have been shown to correlate with clinical parameters and have been utilised as tumour biomarkers to determine the diagnosis and prognosis of several cancer types and monitor the development.

m6A and its modulators are widely studied in hepatocellular cancer, colorectal cancer, and genital and nervous system tumours. However, research on m6A RNA methylation modulators in pancreatic cancer is limited. Recently, He et al. demonstrated that ALKBH5 inhibits pancreatic cancer motility by demethylating long non-coding RNA KCNK15-AS1. Other studies indicate that ALKBH5 decreases WIF-1 RNA methylation and inhibits pancreatic cancer tumorigenesis via the Wnt signalling pathway. In this study, we obtained the expression profiles and clinical data from The Cancer Genome Atlas (TCGA) database of pancreatic cancer to explore the expression of 13 widely reported m6A RNA methylation modulators in PAAD and examine the influence of m6A RNA methylation modulators in the clinical and pathological characteristics of PAAD.

2. Materials And Methods

2.1 Data collection

RNA-seq transcriptome data and corresponding clinical information of patients with PAAD were obtained from TCGA database (https://cancergenome.nih.gov/). We obtained the expression profiles of 178 patients with PAAD and 4 healthy samples. Clinical data of patients are presented in Table 1. Patients with incomplete data on age, gender, survival time (futime), whether they were censored (fustat), pathological grade of the tumour, and World Health Organization classification were excluded. In addition, samples with futime = 0 were also removed and we ultimately included 171 samples for analysis.
Table 1
Association between the expression of five m6A RNA methylation modulators and clinical characteristic in patients with PAAD based on the TCGA datasets

| Risk score | YTHDF1  | ALKBH5  | METTL3  | METTL14 | KIAA1429 |
|-----------|---------|---------|---------|---------|-----------|
|           | β(95%CI)| β(95%CI)| β(95%CI)| β(95%CI)| β(95%CI) |
| age       | 0.032   | -0.018  | -0.149  | -0.087  | -0.108    | -0.074    |
|           | (-0.114,0.357) | (-0.0830.066) | (-0.357,-0.009) | (-0.034,0.009) | (-0.028,0.004) | (-0.031,0.011) |
| gender    | -0.021  | 0.104   | -0.079  | -0.027  | -0.090    | -0.089    |
|           | (-0.071,0.053) | (-0.505,2.731) | (-5.888,1.686) | (-0.556,0.391) | (-0.569,0.135) | (-0.729,0.190) |
| grade     | 0.169   | 0.037   | -0.193  | -0.072  | -0.158    | 0.165     |
|           | (0.006,0.096)* | (-0.893,1.471) | (-6.480,-0.949) | (-0.507,0.185) | (-0.533,-0.019)* | (0.027,0.698)* |
| stage     | 0.153   | -0.155  | -0.252  | -0.120  | -0.22     | 0.013     |
|           | (0.001,0.131)* | (-3.428,-0.036)* | (-10.983,-3.045)* | (-0.888,0.015) | (-0.925,0.187) | (-0.439,0.524) |

2.2 Extraction of m6A RNA methylation modulator expression data

We selected m6A RNA methylation modulators which were widely reported in a variety of cancers. The following 13 m6A RNA methylation modulators were included in this study: METTL3, METTL14, WTAP, RBM15, ZC3H13, and KIAA1429 (writers), FTO and ALKBH5 (erasers), and YTHDF1, YTHDF2, YTHDC1, YTHDC2, and HNRNPC (readers). mRNA expression data were extracted for further bioinformatics analysis.

2.3 Bioinformatics analysis

ActivePerl 5.26 was used to extract the expression of the m6A methylation modulators and clinical data from TCGA database. R 3.6.3 (https://www.perl.org) was used for analyses of the data with the following packages: the limma package analysed the difference in expression between healthy and tumour samples, pheatmap and vioplot packages visually illustrated these differences, the corplot package identified the correlations among the 13 modulators, ROC curve was drawn using the timeROC package, the forestplot package displayed the results of the univariate and multivariate cox analyses, glmnet and survival packages assisted with the LASSO regression, and the rms package portrayed a nomograph to predict the risk of death and the survival rate. STRING database (http://www.string-db.org/) was used to assist with the analysis of the interactions among the 13 m6A RNA methylation regulators.

2.4 Gene set enrichment analysis

PAAD samples were categorised into two groups according to the expression level of the genes of m6A RNA methylation modulators. KEGG pathways of m6A RNA methylation modulator genes were identified by gene set enrichment analysis (GSEA). Gene sets with nominal p-value < 0.05 and false discovery rate (FDR) q-value < 0.25 were considered significantly enriched.

2.5 Statistical analysis

R 3.6.3 was used for our statistical analyses. The differential expression of m6A RNA methylation modulators between cancerous and healthy tissue was compared by the Wilcoxon test. Cox regression analysis was used to examine the
prognosis of pancreatic cancer. Patients with PAAD in TCGA database were separated into a high-risk group and a low-risk group based on the median risk score. Kaplan-Meier method was used to analyses the difference in overall survival (OS) between the two groups and Spearman's correlation was used to explore the correlations among the 13 m6A RNA methylation modulators.

3 Results

3.1 Different expression of m6A RNA methylation modulators in PAAD and healthy tissues

The expression of m6A RNA methylation modulators in PAAD and healthy samples were analysed based on TCGA database. Transcriptome from TCGA showed that most of m6A RNA methylation modulators were not differentially expressed between the two groups except for WTAP (Figs. 1A and 1B), which was lowered in tumour samples (p = 0.012). Further analyses were conducted to explore the correlations and interaction among the 13 modulators. We found the 13 m6A RNA methylation modulators were positively correlated with each other and that the coefficient of association between YTHDC1 and YTHDC2 was the highest. In addition, YTHDC1 expression was highly associated with METTL14 expression and was the only one that was positively correlated with all other modulators. Our analyses revealed that the proteins of m6A regulators showed strong levels of interaction (Figs. 1C and 1D).

3.2 Prognostic value of risk score based on the expression of m6A RNA methylation modulators in PAAD

To discover the influence of m6A RNA methylation modulators in PAAD, we built a risk prediction model. First, we conducted a Cox univariate analysis, which showed that the expression of YTHDF1, ALKBH5, METTL3, KIAA1429, and METTL14 significantly correlated with survival (Fig. 2A). High expression of KIAA1429 was related to lower survival whereas high expression of YTHDF1, ALKBH5, METTL3, and METTL14 decreased the risk of death and acted as protective factors. Variable selection was performed by LASSO Cox regression and the parameter λ indicated that the most suitable model to predict survival included YTHDF1, ALKBH5, METTL3, METTL14, and KIAA1429 with coefficients of -0.023, -0.021, -0.124, -0.178 and 0.233, respectively (Figs. 2B and 2C). The risk score was used to divide the patients into high- and low-risk groups and calculated using the following formula: risk score = Σni=1Coef × xi where Coef represents the coefficient and xi is the expression value of each selected modulators. We found that the survival curve showed significant worse OS in high-risk tumour patients compared with patients in the low-risk group (Fig. 2D).

The expressions of YTHDF1, ALKBH5, METTL3, METTL14, and KIAA1429 were incorporated to form a nomogram to estimate 1-, 3-, and 5-year OS of pancreatic cancer (Fig. 3A). We used calibration curves to examine the precision of the nomogram (Figs. 3B – 3D) and observed that all three calibration curves were close to the ideal curve, which indicated a good prediction value. The result of ROC curve predicted that PAAD patients with high-risk cancer had a 3-year OS rate of 21.8% compared with 44.9% in patients with low-risk cancer (Fig. 3E).

3.3 Risk score correlated with clinical characteristic of patient with PAAD

We investigated the relationship between the risk score from our prediction model and the clinical characteristic of patients with PAAD. Multiple linear regression showed that the risk score was significantly correlated with the grade and stage of the tumour (Table 1), suggesting that a high-risk score corresponded to a high cancer grade and stage. We also analysed the relationship between the expression of m6A RNA methylation modulators and the clinical characteristics
and multivariate regression indicated that the level of expression of all modulators except METTL3 was associated with clinical characteristics of patients with PAAD. The expression of YTHDF1 was inversely correlated with the tumour stage and the expression of ALKBH5 was negatively correlated with age, gender, and tumour stage of patients. Furthermore, METTL14 expression was negatively associated with tumour grade while KIAA1429 expression was correlated positively. Importantly, high expression of ALKBH5 and METTL3 were related to increased survival whereas high expression of KIAA1429 was associated with a low survival.

3.4 Risk score was an independent prognostic indicator

We subsequently hypothesised that risk score could be an independent prognostic indicator and incorporated risk score and relevant clinical and pathological factors such as age, gender, and tumour grade and stage into univariate and multivariate Cox regression to test our hypothesis. Univariate Cox regression revealed that age, tumour grade and stage, and risk score were significantly linked with OS (Fig. 5A). Moreover, age and risk score were still significantly associated with OS in a multivariate Cox regression (Fig. 5B). These results indicated that age and risk score could be independent prognostic indicators of PAAD and we formed a nomogram with age, gender, tumour grade and stage, and risks core to predict 1-, 3-, and 5-year survival of patients with PAAD (Fig. 5C).

3.5 The associated KEGG pathways of m6A RNA methylation modulator genes

To identify the potential biological function of the genes that predicted the OS of patients with PAAD, we used GSEA to search for enriched KEGG pathways. The enrichment score (ES), FDR, and nominal p-value are shown for each gene in Table 2 and the enriched pathways of the five genes are presented in Fig. 6. High expression of Ythdf1 was associated with RNA degradation, cell cycle and base excision repair while low expression of Ythdf1 enriched pathways involving cell adhesion molecules, extracellular matrix receptor interaction, chemokine signalling, and focal adhesion. Alkbh5 expression was linked to chemokine signalling, T cell receptor signalling, JAK-STAT signalling, mTOR signalling and pentose phosphate pathways. In addition, Alkbh5 played a role in the development of renal cell carcinoma and metabolism of xenobiotics by cytochrome P450. Although no gene sets were significantly enriched in the patients with high expression of Mettl13, low Mettl13 expression significantly enriched immune response to pathogenic Escherichia coli infection, glycosphingolipid biosynthesis, and pentose phosphate pathways. Mettl14 participated in chemokine signalling, JAK-STAT signalling, mTOR signalling, T cell receptor signalling, oxidative phosphorylation, DNA replication, ribosome interaction, and renal cell carcinoma. Finally, high expression of Kiaa1429 enriched Wnt signalling, MAPK signalling, ERBB signalling, and pathways involving cell cycle and cancer, although no gene sets were significantly enriched in the patients expressing low levels of Kiaa1429.
Table 2
Gene set enrichment analysis for Ythdf1, Albk5, Mettl13, Mettl114 and Klia1429 with KEGG pathway using GSEA

| NAME                                                                 | ES   | NES  | NOM p-val | FDR q-val |
|----------------------------------------------------------------------|------|------|-----------|-----------|
| **Ythdf1**                                                           |      |      |           |           |
| KEGG_CELL_ADHESION_MOLECULES_CAMS                                    | -0.553 | -2.725 | 0          | 0         |
| KEGG_ECM_RECEPTOR_INTERACTION                                         | -0.520 | -2.395 | 0          | 0         |
| KEGG_CHEMOKINE_SIGNALING_PATHWAY                                      | -0.352 | -1.984 | 0          | 0.003     |
| KEGG_FOCAL_ADHESION                                                   | -0.358 | -1.966 | 0          | 0.003     |
| KEGG_RNA_DEGRADATION                                                  | 0.630  | 1.909  | 0          | 0         |
| KEGG_CELL_CYCLE                                                      | 0.504  | 1.621  | 0          | 0.018     |
| KEGG_BASE_EXCISION_REPAIR                                            | 0.655  | 1.856  | 0          | 0         |
| **Albk5**                                                            |      |      |           |           |
| KEGG_CHEMOKINE_SIGNALING_PATHWAY                                      | 0.575  | 1.730  | 0          | 0.003     |
| KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY                                | 0.591  | 1.707  | 0          | 0.004     |
| KEGG_JAK_STAT_SIGNALING_PATHWAY                                       | 0.548  | 1.622  | 0          | 0.014     |
| KEGG_RENAL_CELL_CARCINOMA                                            | 0.548  | 1.571  | 0          | 0.018     |
| KEGG_MTOR_SIGNALING_PATHWAY                                           | 0.612  | 1.712  | 0.001     | 0.004     |
| KEGG_RIBOSOME                                                        | -0.479 | -2.183 | 0          | 0.002     |
| KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450                    | -0.334 | -1.557 | 0          | 0.152     |
| KEGG_PENTOSE_PHOSPHATE_PATHWAY                                       | -0.389 | -1.460 | 0.037     | 0.143     |
| KEGG_BASE_EXCISION_REPAIR                                            | -0.376 | -1.422 | 0.024     | 0.143     |
| **Mettl13**                                                           |      |      |           |           |
| KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION                            | -0.335 | -1.808 | 0          | 0         |
| KEGG(GLYCOSPHINGOLIPID_BIOSYNTHESIS_LACTO_AND_NEOLACTO_SERIES         | -0.353 | -1.604 | 0          | 0.006     |
| KEGG_PENTOSE_PHOSPHATE_PATHWAY                                       | -0.320 | -1.491 | 0          | 0.012     |
| **Mettl114**                                                          |      |      |           |           |
| KEGG_RIBOSOME                                                        | -0.641 | -2.911 | 0          | 0         |
| KEGG_OXIDATIVE_PHOSPHORYLATION                                       | -0.449 | -2.059 | 0          | 0.002     |
| KEGG_DNA_REPLICATION                                                 | -0.393 | -1.502 | 0.010     | 0.068     |
| KEGG_MTOR_SIGNALING_PATHWAY                                           | 0.653  | 1.781  | 0          | 0.003     |
| KEGG_RENAL_CELL_CARCINOMA                                            | 0.615  | 1.727  | 0          | 0.005     |
| KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY                                | 0.597  | 1.726  | 0          | 0.004     |
| KEGG_JAK_STAT_SIGNALING_PATHWAY                                       | 0.567  | 1.668  | 0          | 0.007     |
| KEGG_CHEMOKINE_SIGNALING_PATHWAY                                      | 0.567  | 1.677  | 0          | 0.008     |
4. Discussion

The high death rate of pancreatic cancer has been a continuous challenge in the field. It can progress rapidly with only mild symptoms and there may be a multitude of causes for pancreatic cancer including a combination of lifestyle, environment, and genetic mutation. Surgery is the preferred treatment for resectable pancreatic cancer with a poor prognosis. Pancreatic cancer is generally insensitive to both chemotherapy and radiotherapy. Therefore, new treatment strategies focusing on the immunotherapy and targeted therapy are urgently needed for patients with pancreatic cancer.

m6A is involved in the development of many cancers and some studies have shown its potential in the treatment of diverse cancers. In this study, we explored the function of m6A RNA methylation modulators in pancreatic cancer according to the transcriptome data from TCGA.

We analysed 13 widely reported m6A RNA methylation modulators in pancreatic cancer and our analyses revealed that WTAP was the only one with differential expression in PAAD patients. However, we did not find a relationship between the expression of WTAP and the clinical prognosis. A high expression of WTAP has been reported in human pancreas cancer cell lines PANC-1, which enhances cell migration and invasion and suppressed its chemoresistance to gemcitabine in a Fak-dependent manner[^34]. Further analysis and research is needed to identify the function of WTAP in PAAD.

We combined the expression of 13 m6A RNA methylation modulators with the clinical parameters of PAAD and Cox univariate analysis indicated that YTHDF1, ALKBH5, METTL3, KIAA1429, and METTL14 were associated with patient survival. Then we used LASSO Cox regression to create a survival prediction model including the five m6A RNA methylation modulators. The resulting risk score had a good prediction of 1-, 3-, and 5-year OS of PAAD and a high-risk score increased the chance for a high grade and stage tumour. Therefore, even though the modulators were not differentially expressed between healthy controls and PAAD patients, their expression was related with OS. Additionally, we discovered that the expression of YTHDF1 showed an inverse relationship with the tumour stage. A previous report described that high expression of YTHDF1 is present in ovarian cancer and promotes cancer progression while knockdown of YTHDF1 inhibits tumorigenesis and peritoneal metastasis[^26]. However, we did not observe similar findings in our study. We also found a negative association between ALKBH5 and tumour stage. Previous studies have demonstrated that ALKBH5 suppresses pancreatic cancer motility by demethylating long non-coding RNA[^32] and a recent study found that decreased ALKBH5 levels predict poor clinical outcome in pancreatic ductal adenocarcinoma, which is consistent with our data. Furthermore, the authors observed that ALKBH5 serves as a tumour suppressor by altering Wnt signalling via a decrease of Wnt inhibitory factor 1 RNA methylation, which in turn inhibits tumorigenesis. A high expression of ALKBH5 also increased sensitivity to chemotherapy[^33]. Expression of METTL3 also affected the risk score and influenced the OS of PAAD patients. However, we did not note any relationship with clinical characteristics. Others have reported that the knockdown of METTL3 in pancreatic cancer cell lines decreases m6A RNA modification modulators and cripples cell proliferation, invasion, and migration. In addition, high METTL3 expression is associated

| NAME                                      | ES   | NES  | NOM p-val | FDR q-val |
|-------------------------------------------|------|------|-----------|-----------|
| Kiaa1429                                  | 0.610| 2.156| 0         | 0.003     |
| KEGG_WNT_SIGNALING_PATHWAY                | 0.602| 2.101| 0         | 0         |
| KEGG_PATHWAYS_IN_CANCER                   | 0.713| 2.052| 0         | 0.001     |
| KEGG_CELL_CYCLE                           | 0.540| 2.026| 0         | 0         |
| KEGG_MAPK_SIGNALING_PATHWAY               | 0.608| 2.033| 0         | 0.001     |
with high pathological and N stage. Additional studies are required to confirm the function of METTL3. Several publications describe that downregulation of METTL14 in pancreatic cancer tissue sensitises the tumour cells to cisplatin by enhancing apoptosis. Autophagy is also improved via an mTOR signalling-dependent pathway. Following these results, we observed reduced expression of METTL14 enriched the mTOR signalling pathway in our GSEA analysis of METTL14. KIAA1429 has been reported to predict poor prognosis in hepatocellular carcinoma patients. We found that KIAA1429 was also a promoter in PAAD and was involved in Wnt signalling, MAPK signalling, ERBB signalling, and pathways in cell cycle and cancer, indicating a central role in the development of PAAD.

A study published in 2019 revealed the regulation mechanism of pentose phosphate-related metabolism in tumour cells, which targets the adjustment of the tumour's cell cycle, affecting the energy requirement of tumour cells. Other studies pointed out that ribosomes involved in epithelial-mesenchymal transition accelerate the metastasis of cancer cells and that chemokines have a regulatory role in immune cell recruitment and tumour and stromal cell biology. These pathways are important in the development of cancer and we also found these to be enriched in high-risk PAAD patients. Taken together, this suggests that the m6A RNA modification modulators mediate these pathways to manage the survival of tumour cells. However, the exact mechanism of action remains to be elucidated with further research.

3. Conclusion

m6A RNA methylation modulators play an important role in the progression of cancer. In this study, we generated a prediction model using 13 m6A RNA methylation modulators in PAAD and identified their association with the prognosis. Our results gain insight into the potential role of m6A RNA methylation in pancreatic cancer.

Abbreviations

PAAD, pancreatic adenocarcinoma; m6A, N6-methyladenosine; TCGA, The Cancer Genome Atlas; METTL3, methyltransferase-like3; METTL14, methyltransferase-like14; WTAP, Wilms’ tumor 1-associating protein; FTO, obesity-associated protein; ALKBH5, α-ketoglutarate-dependent dioxygenase homolog5; YTHDC1, YTH domain-containing 1; YTHDF 1, YT521-B homology domain-containing protein family 1; OS, overall survival; GSEA, gene set enrichment analysis;

Declarations

Acknowledgements

We thank the Editideas team for offering the English language editing services.

Authors’ contributions

LZW, TL and YHX were involved in the study design and writing of the article.

HML involved in downloading the data.

XWL, HHW, and SBL were involved in the data analysis.

EJX and QLC involved in reviewing the manuscript.

All authors reviewed and approved the final manuscript.
Funding
This study was supported by the Anhui Natural Science Foundation (grant number: 9021138205)

Ethic approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors report no conflicts of interest in this work. None of the authors have any personal or financial involvement with organizations that have financial interest in the content of this manuscript.

Availability of data and materials
The data supporting the conclusions of this article are included in the article. The datasets used and/or analyzed in the current study are available from the corresponding author on reasonable request.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020. 70(1): 7-30.
2. Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 2018. 18(1): 688.
3. Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016. 16(9): 553-65.
4. Boccaletto P, Machnicka MA, Purta E, et al. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res. 2018. 46(D1): D303-D307.
5. Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974. 71(10): 3971-5.
6. Desrosiers RC, Friderici KH, Rottman FM. Characterization of Novikoff hepatoma mRNA methylation and heterogeneity in the methylated 5’ terminus. Biochemistry. 1975. 14(20): 4367-74.
7. Liu J, Yue Y, Han D, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014. 10(2): 93-5.
8. Ping XL, Sun BF, Wang L, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014. 24(2): 177-89.
9. Schwartz S, Mumbach MR, Jovanovic M, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5’ sites. Cell Rep. 2014. 8(1): 284-96.
10. Wang X, Feng J, Xue Y, et al. Corrigendum: Structural basis of N6-adenosine methylation by the METTL3-METTL14 complex. Nature. 2017. 542(7640): 260.
11. Moindrot B, Cerase A, Coker H, et al. A Pooled shRNA Screen Identifies Rbm15, Spen, and Wtap as Factors Required for Xist RNA-Mediated Silencing. Cell Rep. 2015. 12(4): 562-72.

12. Patil DP, Chen CK, Pickering BF, et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016. 537(7620): 369-373.

13. Yue Y, Liu J, Cui X, et al. VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018. 4: 10.

14. Knuckles P, Lence T, Haussmann IU, et al. Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m6A machinery component Wtap/Fl(2)d. Genes Dev. 2018. 32(5-6): 415-429.

15. Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011. 7(12): 885-7.

16. Tang C, Klukovich R, Peng H, et al. ALKBH5-dependent m6A demethylation controls splicing and stability of long 3'-UTR mRNAs in male germ cells. Proc Natl Acad Sci U S A. 2018. 115(2): E325-E333.

17. Du H, Zhao Y, He J, et al. YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. Nat Commun. 2016. 7: 12626.

18. Zhou J, Wan J, Gao X, Zhang X, Jaffrey SR, Qian SB. Dynamic m(6)A mRNA methylation directs translational control of heat shock response. Nature. 2015. 526(7574): 591-4.

19. Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015. 518(7540): 560-4.

20. Liu J, Dou X, Chen C, et al. N6-methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription. Science. 2020. 367(6477): 580-586.

21. Berulava T, Buchholz E, Erlerdashvili V, et al. Changes in m6A RNA methylation contribute to heart failure progression by modulating translation. Eur J Heart Fail. 2020. 22(1): 54-66.

22. Livneh I, Moshitch-Moshkovitz S, Amariglio N, Rechavi G, Dominissini D. The m6A epitranscriptome: transcriptome plasticity in brain development and function. Nat Rev Neurosci. 2020. 21(1): 36-51.

23. Gokhale NS, McIntyre A, Mattocks MD, et al. Altered m6A Modification of Specific Cellular Transcripts Affects Flaviviridae Infection. Mol Cell. 2020. 77(3): 542-555.e8.

24. Tran B, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Association between fat-mass-and-obesity-associated (FTO) gene and hip fracture susceptibility. Clin Endocrinol (Oxf). 2014. 81(2): 210-7.

25. Cheng M, Sheng L, Gao Q, et al. The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-kB/MYC signaling network. Oncogene. 2019. 38(19): 3667-3680.

26. Liu T, Wei Q, Jin J, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020.

27. Li Y, Xiao J, Bai J, et al. Molecular characterization and clinical relevance of m6A regulators across 33 cancer types. Mol Cancer. 2019. 18(1): 137.

28. Chen M, Wong CM. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis. Mol Cancer. 2020. 19(1): 44.

29. Chen Y, Wang J, Xu D, et al. m6A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells. Autophagy. 2020: 1-19.

30. Tang C, Xie Y, Yu T, et al. m6A-dependent biogenesis of circular RNAs in male germ cells. Cell Res. 2020. 30(3): 211-228.

31. Ni W, Yao S, Zhou Y, et al. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m6A reader YTHDF3. Mol Cancer. 2019. 18(1): 143.
32. He Y, Hu H, Wang Y, et al. ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15-AS1 Methylation. Cell Physiol Biochem. 2018. 48(2): 838-846.

33. Tang B, Yang Y, Kang M, et al. m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. Mol Cancer. 2020. 19(1): 3.

34. Li BQ, Liang ZY, Seery S, et al. WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer. Cancer Lett. 2019. 451: 48-57.

35. Xia T, Wu X, Cao M, et al. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. Pathol Res Pract. 2019. 215(11): 152666.

36. Kong F, Liu X, Zhou Y, et al. Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells. Int J Biochem Cell Biol. 2020. 122: 105731.

37. Lan T, Li H, Zhang D, et al. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Mol Cancer. 2019. 18(1): 186.

38. Li Y, Yao CF, Xu FJ, et al. APC/CCDH1 synchronizes ribose-5-phosphate levels and DNA synthesis to cell cycle progression. Nat Commun. 2019. 10(1): 2502.

39. Prakash V, Carson BB, Feenstra JM, et al. Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease. Nat Commun. 2019. 10(1): 2110.

40. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017. 17(9): 559-572.

Figures
Figure 1

Expression of m6A RNA methylation modulators in 178 patients with PAAD and 4 normal samples based on TCGA database. The expression levels of 13 m6A RNA methylation modulators in patients with PAAD presented in (A) a heatmap (green means high expression while blue means low expression and blue means normal samples while pink means tumour samples) and (B) a vioplot (blue means normal samples while red means tumour samples). (C) Protein-protein associations among 13 m6A RNA methylation modulators visualised in STRING. (D) Spearman's correlation analysis of the 13 m6A RNA methylation modulators in PAAD patients. *p < 0.05, **p < 0.01, ***p < 0.001.
### Table A

| Gene   | p-value | Hazard Ratio |
|--------|---------|--------------|
| ZC3H13 | 0.956   | 0.997 (0.910 - 1.094) |
| YTHDC2 | 0.239   | 0.866 (0.681 - 1.100) |
| METTL14 | 0.013  | 0.759 (0.610 - 0.943) |
| YTHDF2 | 0.831   | 1.006 (0.950 - 1.065) |
| YTHDC1 | 0.055   | 0.917 (0.839 - 1.002) |
| RBM15  | 0.245   | 1.199 (0.883 - 1.630) |
| FTO    | 0.198   | 0.886 (0.736 - 1.065) |
| ALKBH5 | 0.002   | 0.958 (0.933 - 0.984) |
| KIAA1429 | 0.012 | 1.192 (1.039 - 1.367) |
| HNRNPC | 0.099   | 1.021 (0.996 - 1.047) |
| METTL3 | 0.002   | 0.799 (0.691 - 0.924) |
| YTHDF1 | 0.038   | 0.957 (0.917 - 0.998) |
| WTAP   | 0.258   | 0.963 (0.903 - 1.028) |

### Diagrams

#### B

![Log Lambda](image)

#### C

![Log(lambda)](image)

#### D

![Survival curve](image)
Figure 2

Prognostic value of risk score from m6A RNA methylation modulators expression in PAAD patients. (A) Cox univariate analysis of m6A RNA methylation modulators. (B and C) Selection of genes by LASSO Cox regression. (D) The relationship between the risk score and the OS of patients with PAAD.
Figure 3

Prognostic value of risk score based on the expression of m6A RNA methylation modulators in PAAD. (A) Nomogram predicting 1-, 3-, and 5-year survival of patients with PAAD based on the expression of selected m6A RNA methylation modulators. The top row shows the point value for each variable, rows 2–6 indicate the expression of selected m6A RNA methylation modulators, the sum of these values is located on the Total Points axis, and the line drawn downward to the survival axes is used to determine the likelihood of 1-, 3- or 5-year survival. Calibration of nomograms predicting (B) 1-year, (C) 3-year, and (D) 5-year survival. (E) ROC curves showed the predictive efficiency of the risk signature.
Figure 4

The association between the expression of the selected modulators and survival time. (A) YTHDF1. (B) ALKBH5. (C) METTL3. (D) METTL14. (E) KIAA1429.
Figure 5

Relationship between the risk score, clinical characteristics, and OS in patients with PAAD. (A) Univariate and (B) multivariate Cox regression analyses of the association between clinical and pathological factors including the risk score and OS of PAAD patients. (C) Nomogram based on age, gender, tumour grade and stage, and risk score.
Figure 6

The associated KEGG pathways of m6A RNA methylation genes by GSEA. (A) Ythdf1. (B) Alkbh5. (C) Mettl3. (D) Mettl14. (E) Kiaa1429.